Datavault AI Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Datavault AI Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.09M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $2.67M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $2.08M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.37M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.54M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.40M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $1.67M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.37M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.11M | Mar 29, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.09M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $2.67M | Mar 18, 2026 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.40M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $376.0K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($3.46M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $395.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.86M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $427.0K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($71.0K) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($238.0K) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($158.8K) | Mar 29, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($78.99M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($51.41M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($18.72M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($16.15M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($11.82M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($12.71M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($12.04M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($67.36M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($25.65M) | Mar 29, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($32.48M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($21.14M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($21.46M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($18.04M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($11.51M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($11.29M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($11.16M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($11.57M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($6.84M) | Mar 29, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.50M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $7.82M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $7.46M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.14M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.24M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $4.57M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $5.43M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $4.87M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $3.66M | Mar 29, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.61M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($17.53M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($14.83M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($17.51M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($11.51M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($9.86M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($11.03M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($9.95M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($10.39M) | Mar 29, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $380.0K | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $35.0K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $50.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $43.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $99.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $52.0K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $35.0K | Mar 16, 2021 |
| FY2018 | Dec 31, 2018 | $86.8K | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | $66.0K | Mar 29, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $274.70M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $100.63M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $4.82M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.45M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $19.39M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $11.30M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $4.22M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $5.41M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.46M | Mar 29, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.73M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $14.90M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $9.73M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.45M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.01M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.39M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $3.11M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.59M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $31.22M | Mar 29, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $237.97M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $85.73M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | ($5.16M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | ($2.00M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $16.38M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $7.32M | Mar 17, 2023 |
| FY2020 | Aug 13, 2020 | $11.70M | Mar 16, 2021 |
| FY2021 | Dec 31, 2019 | $594.0K | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $3.82M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | ($94.49M) | Mar 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.14M | Mar 18, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($377.45M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($298.45M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($247.04M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($228.32M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($212.20M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($200.38M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($187.68M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($175.64M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($108.28M) | Mar 29, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.00M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $3.33M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $411.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.90M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $13.11M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $7.42M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $298.0K | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $3.22M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $249.1K | Mar 29, 2019 |
| FY2018 | Dec 31, 2016 | $92.3K | Mar 29, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $668.0K | Mar 11, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (16) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (476) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (82) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (105) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 11, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (16) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (476) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (82) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (105) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 11, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 573.44M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 52.03M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 222,300 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 712,564 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 158,310 | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 8.40M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 1.25M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | 15.37M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | 324,821 | Mar 29, 2019 |